Payment overview · 2025
General Payments
$220.00
12 reported records · 9 companies
Healthcare provider profile · identity verified
Daniel Callaghan, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROCKY HILL, CT · NPI 1124032941
Verified facts
What the public records show
CMS Open Payments records show Daniel Callaghan, MD received $220.00 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.13 | 20.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.75 | 17.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.56 | 14.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.53 | 11.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.34 | 9.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.14 | 8.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.54 | 7.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.25 | 6.9% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $7.76 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $220.00 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.75 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $7.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 523 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 141 |
| Losartan Potassium | Losartan Potassium | 352 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 59 |
| Lisinopril | Lisinopril | 241 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 59 |
| Metformin Hcl | Metformin Hcl | 212 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 61 |
| Sertraline Hcl | Sertraline Hcl | 191 | 56 |
| Simvastatin | Simvastatin | 170 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 35 |
| Omeprazole | Omeprazole | 123 | 33 |
| Alprazolam | Alprazolam | 118 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 32 |
| Eliquis | Apixaban | 116 | 25 |
| Glipizide Er | Glipizide | 113 | 31 |
| Furosemide | Furosemide | 111 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 30 |
| Trazodone Hcl | Trazodone Hcl | 107 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 46 |
| Ezetimibe | Ezetimibe | 77 | 22 |
| Clonazepam | Clonazepam | 67 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Ozempic | Semaglutide | 58 | suppressed |
| Potassium Chloride | Potassium Chloride | 58 | 16 |
| Gabapentin | Gabapentin | 57 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 14 |
| Mirtazapine | Mirtazapine | 54 | 14 |
| Atenolol | Atenolol | 49 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 12 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Fenofibrate | Fenofibrate | 47 | 11 |
| Januvia | Sitagliptin Phosphate | 47 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | 13 |
| Allopurinol | Allopurinol | 45 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Methocarbamol | Methocarbamol | 43 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 12 |
| Finasteride | Finasteride | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | 12 |
| Carvedilol | Carvedilol | 40 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Prednisone | Prednisone | 27 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 11 |
| Tramadol Hcl | Tramadol Hcl | 25 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 15 |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $220.00 · 12 records | Lilly USA, LLC | ABRYSVO, BREZTRI, Fibroscan, INSPIRE, LEQVIO, MOUNJARO, OTEZLA, PREVNAR 20, REPATHA, VRAYLAR, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error